Lv660
3100 积分 2025-11-28 加入
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
4天前
已完结
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
4天前
已完结
From serendipity to strategy: molecular glue degraders in cancer therapeutics
4天前
已完结
Routes to molecular glue degrader discovery
4天前
已完结
Emerging strategies for prospective discovery of molecular glue degraders
4天前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
4天前
已完结
Induced proximity-based therapeutic modalities
4天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
4天前
已完结
Solid-State Interaction of Pharmaceutical Cocrystals with Water Vapor
4个月前
已完结
Improving Channel Hydrate Stability via Localized Chemical Tuning of the Water Environment
4个月前
已完结